Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
The embroiled drugmaker now faces allegations that it violated securities law and that its staff was embedded in Philidor's day-to-day operations.
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
Pfizer increases the financial assistance it gives to patients; Senate committee opens investigation into drug pricing; OptumRx reportedly stopped business with Philidor a year ago
Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.
The public said drugmakers spend too much money on marketing to doctors and patients
Three suggestions for defusing the highly charged pricing atmosphere
The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug
Valeant receives subpoenas over drug pricing; BMS signs new immuno-oncology deal with Five Prime Therapeutics; Pfizer CEO says insurance coverage to blame in price debate
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval
Mylan's marketing of EpiPen raises questions about price; the number of drugs approved through expedited pathways is rising; new combo of old drugs may work for Alzheimer's patients
Turing CEO backs down on price hike; Amgen's and Allergan's cancer biosimilar shows positive results; study finds text message reminders can change health behavior
Craig Rothenberg joined Turing as its first comms chief less than two months ago.
Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus
Clinton expecting to discuss drug prices; Turing criticized for raising the price of infectious-disease drug; online game helps patients reduce blood pressure
Now that the first two PCSK9 inhibitors have been given the thumbs-up by the FDA, the payer community finds itself in a situation comparable to the one it faced upon the arrival of transformative hep.-C drugs: What are they prepared to pay—and which drugs will get the formulary nod? Jaimy Lee assesses the fluid market dynamics
Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic
Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target
The presidential candidate is the latest critic of current laws that prohibit the government from negotiating drug prices for Medicare Part D.
Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.